Part of the GLP-1RA (Liraglutide, Semiglutide) has been verified to be efficacious in the treatment of fatty liver and is employed in the management of T2DM complicated with nonalcoholic fatty liver disease, primarily by ameliorating metabolic dysfunction, insulin resistance, and lipotoxicity of the organs related to its pathogenesis (61), decelerating the fibrosis process and reducing the liver fat content
While results vary from person to person, many clients begin to see changes within the first few weeks of treatment
Drawing from clinical experience and current research, she breaks down how these medications actually work, why microdosing matters, and how to minimize side effects while protecting metabolism, muscle, and long-term health
Why three receptors outperform one Think of it this way
GLP-1 receptor agonists should be used with caution in patients with gastroparesis or severe gastroesophageal reflux disease, with careful monitoring and dose adjustments as needed (36)